Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Изучение когнитивных функций мозга у больных артериальной гипертонией с наличием или отсутствием метаболического синдрома
Изучение когнитивных функций мозга у больных артериальной гипертонией с наличием или отсутствием метаболического синдрома
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Работа посвящена изучению когнитивных функций мозга у больных артериальной гипертонией (АГ) 1–3-й cтепени с наличием или отсутствием метаболического синдрома (МС). В исследовании применялся тест – краткая шкала оценки психического статуса (Мini-Мental State Examination – MMSE) – для изучения общей когнитивной продуктивности мозга больных АГ. Результаты исследования показали, что более выраженные нарушения когнитивных функций мозга были отмечены у больных АГ с наличием МС по сравнению с больными без МС при любой степени тяжести АГ. По нашим данным, вероятность развития поражения мозга у больных АГ с МС почти в 5 раз выше по сравнению с больными АГ без метаболических нарушений. Таким образом, на поражение мозга оказали влияние наличие МС, пол, возраст и степень АГ.
Ключевые слова: артериальная гипертония, метаболический синдром, когнитивная функция мозга.
Key words: arterial hypertension, metabolic syndrome, cognitive function of the brain.
Ключевые слова: артериальная гипертония, метаболический синдром, когнитивная функция мозга.
________________________________________________
Key words: arterial hypertension, metabolic syndrome, cognitive function of the brain.
Полный текст
Список литературы
1. Дедов И.И., Шестакова М.В., Максимова М.А. Федеральная целевая программа «Cахарный диабет». Методические рекомендaции. М., 2002.
2. Мамедов М.Н. Артериальная гипертония – мишень для первичной профилактики сердечно-сосудистых заболеваний. Системные гипертензии. 2007; 1: 27–9.
3. Овчинников А.Г. Ожирение и сердечно-сосудистая система. Сердце. 2005; 4 (5) [23]: 243–53.
4. Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005; с. 265–328, 289–300.
5. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008; с. 7.
6. Шляхто Е.В, Конради А.О. Роль генетических факторов в ремоделировании сердечно-сосудистой системы при гипертонической болезни. Артериальная гипертензия. 2002; 3 (8): 107–14.
7. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177: 361–6887.
8. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West Of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–9.
9. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040–4.
10. Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. В кн.: Руководство по артериальной гипертонии. М.: Медиа Медика, 2005; с. 217–46.
11. Rodgers A, MacMahon S, Gamble G et al. Blood pressure and the risk of stroke in patients with cerebrovascular disease. The United Kingdom Yransient Ishemic Attack Collaborative Group. BMJ 1996; 313: 147.
12. Биверс Т., Лип Г., О'Брайен Э. Артериальная гипертония. М., 2005; с. 13–21.
13. Конради А.О. Антигипертензивная терапия в профилактике и коррекции когнитивных расстройств. Артериальная гипертензия. 2005; 11 (3): 160–3.
14. Breteler MMB, Van Swieten JC, Bots ML et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology 1994; 44: 1246–52.
15. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008; 4 (2): 363–81.
16. Greenland P, Abrams J, Aurigemma GP et al. Prevention Conference V: beyond secondary prevention identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden; Writing Group III. Circulation 2000; 101: E16–22.
17. Hanon O, Leys D. Cognitive decline and dementia in the elderly hypertensive. J Renin Angiotensin Aldosterone Syst 2002; 3 (Suppl. 1): S32–8.
18. Stoks JI, Kannel WB, Wolf PA. Blood pressure as a risk factor for cardiovascular disease. The Framingham study – 30 years of follow-up. Hypertension 1989; 13 (Suppl. 1): 113–8.
19. Salonen RM, Nyyssönen K, Kaikkonen J et al. Antioxidant Supplementation in Atherosclerosis Prevention Study. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107 (7): 947–53.
20. Tatasciore A, Renda G, Zimarino M et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50 (2): 325–32.
21. Buchman AS, Wilson RS, Bienias JL et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65: 892–7.
22. Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991–8.
23. Kalmijn S, Foley D, White L et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese – American elderly men. The Honolulu–Asia aging study. Arteriosder Thromb Vase Biol 2000; 20: 2255–60.
24. Kilander L, Nyman H, Boberg M et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31: 780–6.
25. Kilander L. Cognitive dysfunction in the elderly. The implication of cerebrovascular risk factors. Acta Universitatis Upsaliensis 1997. Uppsala University Library, Uppsala, Sweden.
26. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16.
27. Luchsinger JA, Tang MX, Stern Y et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635–41.
28. Mann JF, Gerstein HC, Dulau-Florea I et al. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int (Suppl.) 2003; 84: S192–6.
29. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results fr om the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–9.
30. Wilkenshoff UM, Sovany A, Kukulski T et al. When, wh ere and to what extent does left ventricular regional function become abnormal with age in normal individuals. A colour Doppler myocardial study. Eur Heart J 1998; 19 (Suppl.): 440.
31. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.
32. Folstein MF. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinican. J Psyhhiatr Res1975; 12: 189–1998.
33. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993; 88: 1444–55.
34. Faraci FM, Baumbach GL, Heistad DD. Cerebral circulation: humoral regulation and effects of chronic hypertension. J Am Soc Nephrol 1990; 1: 53–7.
35. Liu JE, Roman MJ, Pini R et al. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999; 131: 564–72.
36. Kuusisto J, Koivisto K, Mykkanen L et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993; 22: 771–9. xperience. J Hypertens 1991; 9 (Suppl.): S3–S9, 208.
37. Ott A, Stolk RP, Van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 10 (53): 1937–42.
38. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–51.
39. Henon H, Pasquier F, Durieu I et al. Preexisting dementia in stroke patients. Baseline frequency, associated factors and outcome. Stroke 1997; 28: 2429–36.
40. Seux ML, Thijs L, Forette F et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998; 16: 963–9.
41. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008; 4 (2): 363–81.
42. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187–92.
43. Xu WL, Qiu CX, Wahlin A et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63: 1181–6.
44. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–9.
45. Yaffe K, Kanaya A, Lindquist K et al. The Metabolic Syndrome, Inflammation and Risk of Cognitive Decline. JAMA 2004; 292: 2237–42.
46. Kwon HM, Kim BJ, Lee SH et al. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37: 466–70.
47. Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 2006; 67: 843–7.
48. Yates KF, Sweat V, Yau PL et al. Impact of metabolic syndrome on cognition and brain. Arterioscler Thromb Vasc Biol 2012; 32 (9): 2060–7.
2. Мамедов М.Н. Артериальная гипертония – мишень для первичной профилактики сердечно-сосудистых заболеваний. Системные гипертензии. 2007; 1: 27–9.
3. Овчинников А.Г. Ожирение и сердечно-сосудистая система. Сердце. 2005; 4 (5) [23]: 243–53.
4. Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005; с. 265–328, 289–300.
5. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008; с. 7.
6. Шляхто Е.В, Конради А.О. Роль генетических факторов в ремоделировании сердечно-сосудистой системы при гипертонической болезни. Артериальная гипертензия. 2002; 3 (8): 107–14.
7. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177: 361–6887.
8. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West Of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–9.
9. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040–4.
10. Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. В кн.: Руководство по артериальной гипертонии. М.: Медиа Медика, 2005; с. 217–46.
11. Rodgers A, MacMahon S, Gamble G et al. Blood pressure and the risk of stroke in patients with cerebrovascular disease. The United Kingdom Yransient Ishemic Attack Collaborative Group. BMJ 1996; 313: 147.
12. Биверс Т., Лип Г., О'Брайен Э. Артериальная гипертония. М., 2005; с. 13–21.
13. Конради А.О. Антигипертензивная терапия в профилактике и коррекции когнитивных расстройств. Артериальная гипертензия. 2005; 11 (3): 160–3.
14. Breteler MMB, Van Swieten JC, Bots ML et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology 1994; 44: 1246–52.
15. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008; 4 (2): 363–81.
16. Greenland P, Abrams J, Aurigemma GP et al. Prevention Conference V: beyond secondary prevention identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden; Writing Group III. Circulation 2000; 101: E16–22.
17. Hanon O, Leys D. Cognitive decline and dementia in the elderly hypertensive. J Renin Angiotensin Aldosterone Syst 2002; 3 (Suppl. 1): S32–8.
18. Stoks JI, Kannel WB, Wolf PA. Blood pressure as a risk factor for cardiovascular disease. The Framingham study – 30 years of follow-up. Hypertension 1989; 13 (Suppl. 1): 113–8.
19. Salonen RM, Nyyssönen K, Kaikkonen J et al. Antioxidant Supplementation in Atherosclerosis Prevention Study. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107 (7): 947–53.
20. Tatasciore A, Renda G, Zimarino M et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50 (2): 325–32.
21. Buchman AS, Wilson RS, Bienias JL et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65: 892–7.
22. Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991–8.
23. Kalmijn S, Foley D, White L et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese – American elderly men. The Honolulu–Asia aging study. Arteriosder Thromb Vase Biol 2000; 20: 2255–60.
24. Kilander L, Nyman H, Boberg M et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31: 780–6.
25. Kilander L. Cognitive dysfunction in the elderly. The implication of cerebrovascular risk factors. Acta Universitatis Upsaliensis 1997. Uppsala University Library, Uppsala, Sweden.
26. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16.
27. Luchsinger JA, Tang MX, Stern Y et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635–41.
28. Mann JF, Gerstein HC, Dulau-Florea I et al. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int (Suppl.) 2003; 84: S192–6.
29. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results fr om the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–9.
30. Wilkenshoff UM, Sovany A, Kukulski T et al. When, wh ere and to what extent does left ventricular regional function become abnormal with age in normal individuals. A colour Doppler myocardial study. Eur Heart J 1998; 19 (Suppl.): 440.
31. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.
32. Folstein MF. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinican. J Psyhhiatr Res1975; 12: 189–1998.
33. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993; 88: 1444–55.
34. Faraci FM, Baumbach GL, Heistad DD. Cerebral circulation: humoral regulation and effects of chronic hypertension. J Am Soc Nephrol 1990; 1: 53–7.
35. Liu JE, Roman MJ, Pini R et al. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999; 131: 564–72.
36. Kuusisto J, Koivisto K, Mykkanen L et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993; 22: 771–9. xperience. J Hypertens 1991; 9 (Suppl.): S3–S9, 208.
37. Ott A, Stolk RP, Van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 10 (53): 1937–42.
38. Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–51.
39. Henon H, Pasquier F, Durieu I et al. Preexisting dementia in stroke patients. Baseline frequency, associated factors and outcome. Stroke 1997; 28: 2429–36.
40. Seux ML, Thijs L, Forette F et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998; 16: 963–9.
41. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008; 4 (2): 363–81.
42. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187–92.
43. Xu WL, Qiu CX, Wahlin A et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63: 1181–6.
44. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–9.
45. Yaffe K, Kanaya A, Lindquist K et al. The Metabolic Syndrome, Inflammation and Risk of Cognitive Decline. JAMA 2004; 292: 2237–42.
46. Kwon HM, Kim BJ, Lee SH et al. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37: 466–70.
47. Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 2006; 67: 843–7.
48. Yates KF, Sweat V, Yau PL et al. Impact of metabolic syndrome on cognition and brain. Arterioscler Thromb Vasc Biol 2012; 32 (9): 2060–7.
Авторы
Г.Х.Шарипова, И.Е.Чазова, Ю.В.Жернакова
Отдел гипертоний Института клинической кардиологии им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, Москва
Отдел гипертоний Института клинической кардиологии им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.